Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2nd-generation CHIT1 inhibitor (Molecure)
- Development stage
- Preclinical
- Lead developer
- Molecure
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The 2nd-generation CHIT1 inhibitor is a preclinical small-molecule drug candidate developed by Molecure S.A. (formerly OncoArendi Therapeutics). It is designed to selectively inhibit chitotriosidase-1 (CHIT1), an enzyme primarily expressed by activated macrophages that plays a significant role in the pathogenesis of various fibrotic and inflammatory conditions. Unlike the company's lead candidate OATD-01, which is a dual inhibitor of CHIT1 and AMCase, this second-generation program focuses on optimized potency and selectivity for CHIT1 to treat interstitial lung diseases (ILDs) and other fibrotic disorders. By blocking CHIT1 activity, the drug aims to reduce pro-fibrotic signaling and tissue remodeling associated with chronic lung inflammation.
- Other names
- Second-generation CHIT1 inhibitorMolecure 2nd-gen CHIT1 inhibitorMolecure2nd-gen CHIT1 inhibitorMolecure-2nd-gen CHIT1 inhibitorOncoArendi 2nd-generation CHIT1 inhibitorOncoArendi2nd-generation CHIT1 inhibitorOncoArendi-2nd-generation CHIT1 inhibitor
02
Targets
CHIT1 (Chitotriosidase)
Beyond the preview
Go deeper on 2nd-generation CHIT1 inhibitor (Molecure).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2nd-generation CHIT1 inhibitor (Molecure).